Episode Details

Back to Episodes
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

Episode 162 Published 2 years, 4 months ago
Description

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

  • Navitoclax (BCL-XL/BCL-2 inhibitor)
  • Pelabresib (BET inhibitor)
  • Imetelstat (telomerase inhibitor)
  • Luspatercept (erythroid maturation agent)
  • Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV

 

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us